Global Genes
(a leading rare disease patient advocacy organization)

Global Genes (a leading rare disease patient advocacy organization)
Challenge

Global Genes sought to better understand how genes implicated in one rare disease might connect to genes involved in other rare diseases. Traditional literature reviews and siloed databases made it difficult to uncover meaningful interconnections across thousands of conditions—hindering research prioritization, patient grouping, and potential therapeutic repurposing.

How CytoSolve Helped

CytoSolve’s platform integrated thousands of peer-reviewed molecular pathways from published literature into a dynamic, computable systems architecture. Instead of viewing genes in isolation, CytoSolve mapped:

  • Shared downstream molecular mechanisms across seemingly unrelated rare diseases. in silico screening of compound combinations.
  • Common upstream regulators and feedback loops linking multiple genetic mutations.
  • Quantitative synergy scores for gene–gene interactions.

Key Benefits Realized

  • Revealed Hidden Connections
    Identified dozens of previously unrecognized gene interconnections spanning multiple rare disease categories (e.g., neurological, metabolic, and immunological).
  • Prioritized Research Focus
    Enabled Global Genes to highlight clusters of diseases sharing common molecular drivers—guiding funding, awareness campaigns, and collaborative research initiatives more effectively.
  • Accelerated Insight Generation
    What would have taken years of manual literature review was accomplished in weeks using CytoSolve’s scalable computational approach.
  • Empowered Advocacy
    Provided scientifically robust, visualizable data that Global Genes could share with researchers, pharma partners, and patient communities to demonstrate biological overlap and justify cross-disease collaboration.

Outcome

Global Genes gained a comprehensive, systems-level view of gene interconnectivity across rare diseases—transforming advocacy from disease-specific silos into a more unified, mechanism-driven strategy that accelerates research and hope for thousands of patients.

This collaboration exemplifies how CytoSolve’s infrastructure reveals the true systems architecture of biology—beyond isolated genes—to drive meaningful progress in complex disease landscapes.